Balance Sheet
Accounts PayablesAssetsCommon EquityLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Exousia Bio (LMMY) Receivables (2023 - 2024)

Lamy (LMMY) has disclosed Receivables for 2 consecutive years, with $16689.0 as the latest value for Q4 2024.

  • Quarterly Receivables rose 330.68% to $16689.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $16689.0 through Nov 2024, up 330.68% year-over-year, with the annual reading at $11936.0 for FY2024, N/A changed from the prior year.
  • Receivables hit $16689.0 in Q4 2024 for Lamy, up from $16117.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $16689.0 in Q4 2024 to a low of $3875.0 in Q4 2023.